The financing round was jointly led by new investor Regeneron Ventures and current investor Deerfield Management.

US biotech Actio Biosciences has raised $66 million in a series B round to support its pipeline of genetically targeted ...

With backers such as Regeneron’s venture arm, Actio Biosciences is working on medicines that counter a wide range of ...

ABS-0871 is a potential first-in-class oral, small molecule TRPV4 inhibitorfor the treatment of CMT2C, a rare inherited disorder that affects both motor and sensory functions with a U.S ...

Enrollment ongoing in Phase 1 trial for ABS-0871, a TRPV4 inhibitor for the treatment of Charcot-Marie-Tooth disease type 2C. SAN DIEGO, June 18, 2025--(BUSINESS WIRE)--Actio Biosciences, a ...

The startup is one of several that have recently raised mega rounds of financing to support programs in the clinic or ...

Trpv4-/- mice resisted TGFβ2-driven increases in IOP. These data establish a fundamental role of TGFβ as a modulator of mechanosensing and identifies TRPV4 channel as a common mechanism for TM ...

Cell polarity is the asymmetric organisation of several cellular components, including its plasma membrane, cytoskeleton or organelles. This asymmetry can be used for specialised functions, such ...

Trpv4-/-mice (N = 6) were injected with LV-TGFβ2 and LV-Ctrl vectors in contralateral eyes (Figure 5 C ). Additionally, two littermate control mice injected alongside the Trpv4-/-animals were added to ...

The TRPV4 channel is pivotal in blood pressure regulation and is widely expressed in VSMCs of various arteries. 43 Trpv4 SMC −/− mice display lower resting blood pressure because of increased ...